Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 271

1.

Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV Network.

Coffin CS, Ramji A, Cooper CL, Miles D, Doucette KE, Wong P, Tam E, Wong DK, Wong A, Ukabam S, Bailey RJ, Tsoi K, Conway B, Barrett L, Michalak TI, Congly SE, Minuk G, Kaita K, Kelly E, Ko HH, Janssen HLA, Uhanova J, Lethebe BC, Haylock-Jacobs S, Ma MM, Osiowy C, Fung SK; Canadian HBV Network.

CMAJ Open. 2019 Oct 22;7(4):E610-E617. doi: 10.9778/cmajo.20190103. Print 2019 Oct-Dec.

2.

Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells.

Leung Z, Ko FCF, Tey SK, Kwong EML, Mao X, Liu BHM, Ma APY, Fung YME, Che CM, Wong DKH, Lai CL, Ng IO, Yam JWP.

J Exp Clin Cancer Res. 2019 Oct 22;38(1):423. doi: 10.1186/s13046-019-1402-x.

3.

Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).

Liem KS, Fung S, Wong DK, Yim C, Noureldin S, Chen J, Feld JJ, Hansen BE, Janssen HLA.

Gut. 2019 Dec;68(12):2206-2213. doi: 10.1136/gutjnl-2019-318981. Epub 2019 Aug 28.

PMID:
31462554
4.

Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma.

To WP, Mak LY, Wong DK, Fung J, Liu F, Seto WK, Lai CL, Yuen MF.

J Viral Hepat. 2019 Dec;26(12):1473-1480. doi: 10.1111/jvh.13191. Epub 2019 Sep 2.

PMID:
31418973
5.

Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP53 genes in HBV-associated hepatocellular carcinoma.

Huang FY, Wong DK, Tsui VW, Seto WK, Mak LY, Cheung TT, Lai KK, Yuen MF.

BMC Cancer. 2019 Aug 8;19(1):789. doi: 10.1186/s12885-019-6002-9.

6.

Amplified oxygen reduction signal at a Pt-Sn-modified TiO2 nanocomposite on an electrochemical aptasensor.

Li L, Liu X, Yang L, Zhang S, Zheng H, Tang Y, Wong DKY.

Biosens Bioelectron. 2019 Oct 1;142:111525. doi: 10.1016/j.bios.2019.111525. Epub 2019 Jul 23.

PMID:
31369944
7.

In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue.

Mak LY, Liu SH, Yap DY, Seto WK, Wong DK, Fung J, Chan TM, Lai CL, Yuen MF.

Dig Dis Sci. 2019 Jul 6. doi: 10.1007/s10620-019-05717-0. [Epub ahead of print]

PMID:
31280390
8.

Among Patients with Undetectable Hepatitis B Surface Antigen and Hepatocellular Carcinoma, a High Proportion Has Integration of HBV DNA into Hepatocyte DNA and No Cirrhosis.

Wong DK, Cheng SCY, Lung-Yi Mak L, Wai-Pan To E, Cheuk-Lam Lo R, Cheung TT, Seto WK, Fung J, Man K, Lai CL, Yuen MF.

Clin Gastroenterol Hepatol. 2019 Jun 25. pii: S1542-3565(19)30667-6. doi: 10.1016/j.cgh.2019.06.029. [Epub ahead of print]

PMID:
31252193
9.

Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co-infected Adults.

Sterling RK, King WC, Wahed AS, Kleiner DE, Khalili M, Sulkowski M, Chung RT, Jain MK, Lisker-Melman M, Wong DK, Ghany MG; HIV-HBV Cohort Study of the Hepatitis B Research Network.

Hepatology. 2019 Jun 20. doi: 10.1002/hep.30825. [Epub ahead of print]

PMID:
31220357
10.

Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.

Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, Manns M, Kaita K, Krastev Z, Lee SS, Cathcart AL, Crans G, Op den Brouw M, Jump B, Gaggar A, Flaherty J, Buti M.

Liver Int. 2019 Oct;39(10):1868-1875. doi: 10.1111/liv.14155. Epub 2019 Jul 10.

PMID:
31136052
11.

Metastatic Pleomorphic Adenoma in the infratemporal fossa and neck following total parotidectomy after 30 years.

Wong DKC, Muhamad NS, Sobri SS, Amin WAM, Yusof Z.

Med J Malaysia. 2019 Apr;74(2):85-86.

12.

Plasma Fibronectin Levels Identified via Quantitative Proteomics Profiling Predicts Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B.

Liu F, Seto WK, Wong DK, Huang FY, Cheung KS, Mak LY, Sharma R, Zhang S, Fung J, Lai CL, Yuen MF.

J Infect Dis. 2019 Aug 9;220(6):940-950. doi: 10.1093/infdis/jiz223.

PMID:
31056649
13.

Probable hepatotoxicity with dolutegravir: report of two cases and review of the literature.

Nhean S, Yoong D, Wong DK, Gough K, Tseng AL.

AIDS. 2019 Jun 1;33(7):1261-1263. doi: 10.1097/QAD.0000000000002191. No abstract available.

PMID:
31045944
14.

Distinct phenotype and function of circulating Vδ1+ and Vδ2+ γδT-cells in acute and chronic hepatitis B.

Chang KM, Traum D, Park JJ, Ho S, Ojiro K, Wong DK, Wahed AS, Terrault NA, Khalili M, Sterling RK, Janssen HLA, Shuhart MC, Lau DT, Roberts LR, Johnson GS, Kaplan DE, Betts MR, Lee WM, Lok ASF; Hepatitis B Research Network (HBRN).

PLoS Pathog. 2019 Apr 18;15(4):e1007715. doi: 10.1371/journal.ppat.1007715. eCollection 2019 Apr.

15.

exRNA Atlas Analysis Reveals Distinct Extracellular RNA Cargo Types and Their Carriers Present across Human Biofluids.

Murillo OD, Thistlethwaite W, Rozowsky J, Subramanian SL, Lucero R, Shah N, Jackson AR, Srinivasan S, Chung A, Laurent CD, Kitchen RR, Galeev T, Warrell J, Diao JA, Welsh JA, Hanspers K, Riutta A, Burgstaller-Muehlbacher S, Shah RV, Yeri A, Jenkins LM, Ahsen ME, Cordon-Cardo C, Dogra N, Gifford SM, Smith JT, Stolovitzky G, Tewari AK, Wunsch BH, Yadav KK, Danielson KM, Filant J, Moeller C, Nejad P, Paul A, Simonson B, Wong DK, Zhang X, Balaj L, Gandhi R, Sood AK, Alexander RP, Wang L, Wu C, Wong DTW, Galas DJ, Van Keuren-Jensen K, Patel T, Jones JC, Das S, Cheung KH, Pico AR, Su AI, Raffai RL, Laurent LC, Roth ME, Gerstein MB, Milosavljevic A.

Cell. 2019 Apr 4;177(2):463-477.e15. doi: 10.1016/j.cell.2019.02.018.

16.

Serum Mac-2 binding protein glycosylation isomer level predicts hepatocellular carcinoma development in E-negative chronic hepatitis B patients.

Mak LY, To WP, Wong DK, Fung J, Liu F, Seto WK, Lai CL, Yuen MF.

World J Gastroenterol. 2019 Mar 21;25(11):1398-1408. doi: 10.3748/wjg.v25.i11.1398.

17.
18.

Association of adipokines with hepatic steatosis and fibrosis in chronic hepatitis B patients on long-term nucleoside analogue.

Mak LY, Lee CH, Cheung KS, Wong DK, Liu F, Hui RW, Fung J, Xu A, Lam KS, Yuen MF, Seto WK.

Liver Int. 2019 Jul;39(7):1217-1225. doi: 10.1111/liv.14104. Epub 2019 Apr 11.

PMID:
30912255
19.

Prevalence and predictors of complementary and alternative medicine modalities in patients with chronic hepatitis B.

Liem KS, Yim C, Ying TD, Zanjir WR, Fung S, Wong DK, Shah H, Feld JJ, Hansen BE, Janssen HLA.

Liver Int. 2019 Aug;39(8):1418-1427. doi: 10.1111/liv.14105. Epub 2019 Apr 22.

PMID:
30912219
20.

Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval.

Mak LY, Seto WK, Hui RW, Fung J, Wong DK, Lai CL, Yuen MF.

J Viral Hepat. 2019 Jul;26(7):818-827. doi: 10.1111/jvh.13095. Epub 2019 Apr 16.

PMID:
30895682
21.

Noninvasive Predictors of High-Risk Varices in Patients with Non-Cirrhotic Portal Hypertension.

Cunningham ME, Parastandeh-Chehr G, Cerocchi O, Wong DK, Patel K.

Can J Gastroenterol Hepatol. 2019 Feb 7;2019:1808797. doi: 10.1155/2019/1808797. eCollection 2019.

22.

Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials.

Buti M, Wong DK, Gane E, Flisiak R, Manns M, Kaita K, Janssen HLA, Op den Brouw M, Jump B, Kitrinos K, Crans G, Flaherty J, Gaggar A, Marcellin P.

Lancet Gastroenterol Hepatol. 2019 Apr;4(4):296-304. doi: 10.1016/S2468-1253(19)30015-9. Epub 2019 Feb 20.

PMID:
30795958
23.

Serum Mac-2-binding protein glycosylation isomer and risk of hepatocellular carcinoma in entecavir-treated chronic hepatitis B patients.

Mak LY, Ko M, To E, Wong DK, Ma JH, Hui TL, Seto WK, Fung J, Lai CL, Yuen MF.

J Gastroenterol Hepatol. 2019 Feb 20. doi: 10.1111/jgh.14637. [Epub ahead of print]

PMID:
30786068
24.

Correlation of serum Mac-2-binding protein glycosylation isomer (M2BPGi) and liver stiffness in chronic hepatitis B infection.

Mak LY, Wong DK, Seto WK, Ning Q, Cheung KS, Fung J, Lai CL, Yuen MF.

Hepatol Int. 2019 Mar;13(2):148-156. doi: 10.1007/s12072-019-09928-5. Epub 2019 Jan 22.

PMID:
30671807
25.

A Territorywide Prevalence Study on Blood-Borne and Enteric Viral Hepatitis in Hong Kong.

Liu KSH, Seto WK, Lau EHY, Wong DK, Lam YF, Cheung KS, Mak LY, Ko KL, To WP, Law MWK, Wu JT, Lai CL, Yuen MF.

J Infect Dis. 2019 May 24;219(12):1924-1933. doi: 10.1093/infdis/jiz038.

PMID:
30668746
26.

Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study.

Sterling RK, Wahed AS, King WC, Kleiner DE, Khalili M, Sulkowski M, Chung RT, Jain MK, Lisker-Melman M, Wong DK, Ghany MG; HIV-HBV Cohort Study of the Hepatitis B Research Network.

Am J Gastroenterol. 2019 May;114(5):746-757. doi: 10.1038/s41395-018-0409-9.

PMID:
30410040
27.

Monitoring and Treatment of Patients Undergoing Immunotherapy With Anti-CD20 Who are Exposed to HBV.

Seto WK, Chan TS, Hwang YY, Mak LY, Wong DK, Fung J, Liu KS, Cheung KS, Lai CL, Kwong YL, Yuen MF.

Clin Gastroenterol Hepatol. 2019 Jun;17(7):1410-1412. doi: 10.1016/j.cgh.2018.09.020. Epub 2018 Sep 19.

PMID:
30243760
28.

Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection.

Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF.

Clin Transl Gastroenterol. 2018 Jun 19;9(6):163. doi: 10.1038/s41424-018-0020-9.

29.

Evolution and Diversity of Pre-mRNA Splicing in Highly Reduced Nucleomorph Genomes.

Wong DK, Grisdale CJ, Fast NM.

Genome Biol Evol. 2018 Jun 1;10(6):1573-1583. doi: 10.1093/gbe/evy111.

30.

A photoelectrochemical aptasensor based on a 3D flower-like TiO2-MoS2-gold nanoparticle heterostructure for detection of kanamycin.

Liu X, Liu P, Tang Y, Yang L, Li L, Qi Z, Li D, Wong DKY.

Biosens Bioelectron. 2018 Jul 30;112:193-201. doi: 10.1016/j.bios.2018.04.041. Epub 2018 Apr 19.

PMID:
29705617
31.

Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.

Fung J, Cheung KS, Wong DK, Mak LY, To WP, Seto WK, Lai CL, Yuen MF.

Hepatology. 2018 Aug;68(2):462-472. doi: 10.1002/hep.29874. Epub 2018 Jun 6.

PMID:
29534307
32.

The role for hepatitis A vaccination in HIV pre-exposure prophylaxis.

Ismail MF, Wong DK, Bogoch II.

AIDS. 2018 Mar 13;32(5):675-676. doi: 10.1097/QAD.0000000000001742. No abstract available.

PMID:
29494426
33.

Isolation of Plasma Lipoproteins as a Source of Extracellular RNA.

Li K, Wong DK, Luk FS, Kim RY, Raffai RL.

Methods Mol Biol. 2018;1740:139-153. doi: 10.1007/978-1-4939-7652-2_11.

34.
35.

Hepatitis B core protein as a therapeutic target.

Mak LY, Wong DK, Seto WK, Lai CL, Yuen MF.

Expert Opin Ther Targets. 2017 Dec;21(12):1153-1159. doi: 10.1080/14728222.2017.1397134. Epub 2017 Nov 1. Review.

PMID:
29065733
36.

Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection.

Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF.

Aliment Pharmacol Ther. 2018 Jan;47(1):43-54. doi: 10.1111/apt.14376. Epub 2017 Oct 16. Review.

37.

Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B.

Seto WK, Hui RWH, Mak LY, Fung J, Cheung KS, Liu KSH, Wong DK, Lai CL, Yuen MF.

Clin Gastroenterol Hepatol. 2018 Apr;16(4):575-583.e2. doi: 10.1016/j.cgh.2017.09.044. Epub 2017 Sep 29.

PMID:
28970146
38.

A TiO2 nanosheet-g-C3N4 composite photoelectrochemical enzyme biosensor excitable by visible irradiation.

Liu P, Huo X, Tang Y, Xu J, Liu X, Wong DKY.

Anal Chim Acta. 2017 Sep 1;984:86-95. doi: 10.1016/j.aca.2017.06.043. Epub 2017 Jun 30.

PMID:
28843572
39.

Inverse relationship between hepatic steatosis and hepatitis B viremia: Results of a large case-control study.

Hui RWH, Seto WK, Cheung KS, Mak LY, Liu KSH, Fung J, Wong DK, Lai CL, Yuen MF.

J Viral Hepat. 2018 Jan;25(1):97-104. doi: 10.1111/jvh.12766. Epub 2017 Aug 25.

PMID:
28772340
40.

Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts liver cancer development in chronic hepatitis B patients under antiviral treatment.

Cheung KS, Seto WK, Wong DK, Mak LY, Lai CL, Yuen MF.

Oncotarget. 2017 Jul 18;8(29):47507-47517. doi: 10.18632/oncotarget.17670.

41.

Role of hepatitis B core protein in HBV transcription and recruitment of histone acetyltransferases to cccDNA minichromosome.

Chong CK, Cheng CYS, Tsoi SYJ, Huang FY, Liu F, Seto WK, Lai CL, Yuen MF, Wong DK.

Antiviral Res. 2017 Aug;144:1-7. doi: 10.1016/j.antiviral.2017.05.003. Epub 2017 May 10.

PMID:
28499864
42.

Deep sequencing analysis of quasispecies in the HBV pre-S region and its association with hepatocellular carcinoma.

Zhang AY, Lai CL, Huang FY, Seto WK, Fung J, Wong DK, Yuen MF.

J Gastroenterol. 2017 Sep;52(9):1064-1074. doi: 10.1007/s00535-017-1334-1. Epub 2017 Mar 28.

PMID:
28353014
43.

Interplay between SIRT1 and hepatitis B virus X protein in the activation of viral transcription.

Deng JJ, Kong KE, Gao WW, Tang HV, Chaudhary V, Cheng Y, Zhou J, Chan CP, Wong DK, Yuen MF, Jin DY.

Biochim Biophys Acta Gene Regul Mech. 2017 Apr;1860(4):491-501. doi: 10.1016/j.bbagrm.2017.02.007. Epub 2017 Feb 24.

PMID:
28242208
44.

Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy.

Cheung KS, Seto WK, Wong DK, Lai CL, Yuen MF.

J Viral Hepat. 2017 Aug;24(8):654-661. doi: 10.1111/jvh.12688. Epub 2017 Mar 13.

PMID:
28185363
45.

The role of interleukin-27 in predicting spontaneous HBeAg seroconversion in chronic hepatitis B infection.

Li J, Mak LY, Wong DK, Fung J, Seto WK, Lai CL, Yuen MF.

Liver Int. 2017 Sep;37(9):1287-1294. doi: 10.1111/liv.13372. Epub 2017 Feb 10.

PMID:
28111892
46.

Congenital epulis: A rare benign tumour.

Wong DK, Ramli R, Muhaizan WM, Primuharsa Putra SH.

Med J Malaysia. 2016 Oct;71(5):300-301.

47.

Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study.

Seto WK, Chan TS, Hwang YY, Wong DK, Fung J, Liu KS, Gill H, Lam YF, Lau EHY, Cheung KS, Lie AKW, Lai CL, Kwong YL, Yuen MF.

Hepatology. 2017 May;65(5):1451-1461. doi: 10.1002/hep.29022. Epub 2017 Mar 22.

PMID:
28027590
48.

Hepatitis B virus core-related antigen as a surrogate marker for covalently closed circular DNA.

Wong DK, Seto WK, Cheung KS, Chong CK, Huang FY, Fung J, Lai CL, Yuen MF.

Liver Int. 2017 Jul;37(7):995-1001. doi: 10.1111/liv.13346. Epub 2017 Jan 28.

PMID:
27992681
49.

Association of Hepatitis B Core-Related Antigen With Hepatitis B Virus Reactivation in Occult Viral Carriers Undergoing High-Risk Immunosuppressive Therapy.

Seto WK, Wong DK, Chan TS, Hwang YY, Fung J, Liu KS, Gill H, Lam YF, Cheung KS, Lie AK, Lai CL, Kwong YL, Yuen MF.

Am J Gastroenterol. 2016 Dec;111(12):1788-1795. doi: 10.1038/ajg.2016.436. Epub 2016 Sep 20. Erratum in: Am J Gastroenterol. 2016 Dec;111(12 ):1858.

PMID:
27644733
50.

Hepatotoxicity and potential drug interaction with ledipasvir/sofosbuvir in HIV/HCV infected patients.

Tseng A, Wong DK.

J Hepatol. 2016 Sep;65(3):651-3. doi: 10.1016/j.jhep.2016.05.015. Epub 2016 May 20. No abstract available.

PMID:
27210428

Supplemental Content

Support Center